AUTHORS
Rahul Kumar Thakur, MD, Nisha M. Nair2, Chelsea Peterson, DO3, Alex Niu, MD4, Alicia Lieberman, MD5, Grant Schofield, MD, MSc (MED), FRCPC6, Ehsan Malek, MD7, Maureen Ross, MD, PhD8, Philip L. McCarthy, MD9, Marco Davila, MD, PhD10, Brian C. Betts, MD11, Shernan Holtan, MD12, Megan M Herr, PhD13
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
13 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Background:
Recipient inflammatory status before allogeneic hematopoietic cell transplantation (allo-HCT) may influence susceptibility to graft-versus-host disease (GVHD) and other transplant-related complications. Amphiregulin (AREG), an epidermal growth factor receptor ligand involved in tissue repair, and CXCL9, an interferon-γ-inducible chemokine that mediates recruitment of activated CXCR3+ immune cells, represent distinct pathways implicated in GVHD pathogenesis, Elevated AREG and CXCL9 after allo-HCT have been associated with GVHD and adverse outcomes, but their prognostic significance before conditioning and donor immune exposure remains unexplored
Objective:
We evaluated whether pretransplant AREG and CXCL9 identify recipient biological vulnerability to subsequent GVHD and adverse outcomes after allo-HCT.
Methods:
We performed a retrospective cohort study of consecutive adult patients undergoing allo-HCT between 2018 and 2025 with prospectively banked pre-conditioning serum available through the institutional biorepository. Pretransplant AREG and CXCL9 concentrations were evaluated separately and stratified into tertiles. Outcomes included overall survival (OS), progression-free survival (PFS), grade II-IV and III-IV acute GVHD, chronic GVHD, and relapse. OS and PFS were estimated using Kaplan-Meier methods and compared using log-rank tests. Cumulative incidence functions accounting for competing risks were used for GVHD and relapse and compared using Gray's test. Multivariable Cox proportional hazards regression was performed to evaluate the independent association with 1-year OS, PFS, and NRM.
Results:
In 152 allo-HCT recipients with available pre-conditioning serum, median age was 61 years (range, 19–81), 58% were aged ≥60 years, and 62% were male. Diagnoses included AML (44%), MDS (20%), and other leukemias (28%); 53% of patients underwent transplantation in complete remission. Most patients received reduced intensity/non-myeloablative conditioning (87%), and peripheral blood stem cell grafts (94%); matched unrelated donor transplantation (51%) of transplants. Pretransplant AREG tertiles were <0.64, 0.64–3.08, and ≥3.09, while CXCL9 tertiles were <5.1, 5.1–13.5, and ≥13.6. One-year overall survival was 69%, with infection (38%), disease progression (30%), and GVHD (19%) as the leading causes of death.
Higher pretransplant AREG was associated with inferior OS (log-rank P=0.04), increased cumulative incidence of grade II-IV acute GVHD (Gray's P=0.01), grade III-IV acute GVHD (P=0.02), and chronic GVHD (P=0.02), but was not significantly associated with PFS. Similarly, higher pretransplant CXCL9 was associated with inferior OS (P=0.0001), inferior PFS (P=0.001), and increased grade II-IV acute GVHD (P=0.007). CXCL9 was not significantly associated with Grade III-IV acute GVHD nor chronic GVHD. Neither AREG nor CXCL9 showed a significant association with relapse in this cohort (Gray’s P=0.2 and P=0.7, respectively)
On multivariable analyses, higher pre-transplant AREG was associated with a higher risk of death and NRM at 1-year, but not PFS (OS: HR=2.04, P=0.07; NRM: HR=4.85, P=0.01; PFS: HR=1.45, P=0.3). CXCL9 was associated with a higher risk of death, NRM, and PFS at 1-year (OS: HR=2.65, P=0.03; NRM: HR=6.05, P=0.02; PFS: HR=2.44, P=0.02).
Conclusions:
Elevated pretransplant AREG and CXCL9 were associated with subsequent GVHD and inferior survival following allo-HCT, suggesting that clinically relevant differences in recipient tissue-repair and inflammatory pathways are detectable before transplantation. While both biomarkers identified recipients at increased risk for acute and chronic GVHD, they demonstrated distinct prognostic profiles, with AREG independently associated with non-relapse mortality and CXCL9 independently predicting overall survival, progression-free survival, and non-relapse mortality. These findings support the use of pretransplant biomarker assessment to refine biologically informed risk stratification before allo-HCT and warrant prospective validation.
DISCLOSURES
Rahul Kumar Thakur, MD: No relevant conflicts of interest to declare.